SAN DIEGO and SHANGHAI, February 09, 2021 – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today the appointment of Haijun Dong, PhD, MBA as … Read more
SAN DIEGO and SHANGHAI, February 09, 2021 – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today the appointment of Haijun Dong, PhD, MBA … Read more
SAN DIEGO & SHANGHAI, January 18, 2021 — BioDuro-Sundia received the “2020 EXCELLENT Team Service” award from Lynk Pharmaceuticals, as recognition of the efforts and contributions made by the BioDuro-Sundia … Read more
Congratulations to DartsBio Pharmaceutical (Guangdong) Co., Ltd. (hereinafter referred to as “DartsBio”) for their self-developed human recombinant monoclonal antibody DS002 targeting NGF has been approved by NMPA for clinical trial. … Read more
Congratulations to GenFleet Therapeutics Inc. for their selective CDK9 inhibitor GFH009 Injection have been approved by the CDE (Center for Drug Evaluation), NMPA for clinical trials. It has received US … Read more
Congratulations to InnoCare Pharma Limited (hereinafter as ” InnoCare”) for its BTK inhibitor Orelabrutinib has been officially approved by NMPA for commercial! The potential indications of Orelabrutinib are mainly for … Read more
SAN DIEGO, May 26, 2020 — BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholic steatohepatitis (NASH) that … Read more
SAN DIEGO & SHANGHAI, December 03, 2020 — BioDuro LLC, a leading global life sciences contract research, development and manufacturing organization (CRDMO), and Silexon, a cutting-edge AI-empowered biotechnology company using … Read more
Congratulations to TaiGen Biotechnology Company, Limited (“TaiGen”) for the new influenza antiviral drug TG-1000 receiving the US Food and Drug Administration (FDA) approval for clinical trial application (IND). TG-1000 is … Read more
David Preston has had 38 years of healthcare experience with publicly – Traded and Private companies in the fields of Pharmaceutical’s, Animal Health and Biotechnology as a Board Member. The last 30 years of his experience has been in China, Taiwan and Hong Kong building successful high growth businesses. David Has been Chairman and CEO for Greater China for Sanofi and Boehringer – Ingelheim as well as the Janssen Corporation since 1991 in China. During this time he built high Growth businesses in China through diversified strategies in Innovative Pharmaceuticals, branded Generics, Biotechnology, and Animal Healthcare.
Key highlights in this period included building of the first Western Multinational Biotechnology C.M.O. facility as well as obtaining the first Test C.M.O.[ MAH] license. Establishment of a number of High tech Vaccine Plants, and R and D facilities in the field of Animal Health. Signing and development of numerous JV’s as well as Wholly owned Subsidiaries, Mergers and Acquisitions across Pharmaceutical’s, Animal Health, and Biotechnology industries.
David’s achievements in the Healthcare industry and it Growth and development in China is widely recognized by the Chinese Government and the City of Shanghai. In 2013 he was awarded the Silver Magnolia followed in 2015 the Gold Magnolia award. This was then followed by being awarded in 2017 the Honorary Citizen of Shanghai by 40th People’s Municipal Congress of Shanghai. David holds a Business Science Degree
This will close in 0 seconds
This will close in 0 seconds
This will close in 0 seconds
Michael Miltenberger joined Advent in 2011 as an associate in the healthcare team. Following business school, he rejoined Advent’s Boston office, focusing on healthcare investments. Prior to Advent, Michael was a consultant at McKinsey & Company in their Washington DC office, serving a range of healthcare and private equity clients. Michael earned a BA, cum laude, from Harvard College and an MBA from Harvard Business School, graduating with High Distinction as a Baker Scholar and a Harvey Fellow.
This will close in 0 seconds
Dr. Masood Tayebi is the Founder of BioDuro. He currently serves as CEO of a nationwide real estate portfolio and is a Partner and Chief Executive Officer of the Bridgewest Group. Prior to BioDuro, Dr. Tayebi was Co-Founder and Chairman of Wireless Facilities, Inc. (NASDAQ: WFI), a global leader in telecommunications outsourcing.
This will close in 0 seconds
This will close in 0 seconds
Amit Patel has twenty years of healthcare industry experience with publicly-traded, private equity-backed, and start-up companies in the capacity of executive, board member, advisor, and investor. He is currently Executive Chairman of Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company) and a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma. Recently, Amit was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017).
Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc. as EVP & Head of North America, and SVP & Head of Global Corporate Development & Strategic Planning. Earlier, Amit was VP of Corporate Development at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS). He started his career as a strategy consultant with Marakon Associates. Amit holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania
This will close in 0 seconds
Dr. Haijun Dong currently serves as global CEO of BioDuro-Sundia. He previously was CEO for over 5 years at PharmaBlock Sciences Inc., a public company listed in the Shenzhen Stock Exchange (300725.SZ). The positions he held prior to PharmaBlock includes, among others, Senior Scientist at Boehringer Ingelheim Pharmaceuticals in Ridgefield, Connecticut; Senior Principal Scientist at Roche in Nutley, New Jersey; Head of DMPK and Drug Safety at Roche China R&D Company in Shanghai; Chief Operating Officer of Eli Lilly China R&D Center in Shanghai.
Dr. Dong received his PhD in organic chemistry from the University of Washington in Seattle, Washington, and MBA from China Europe International Business School in Shanghai.
This will close in 0 seconds
Teo Nee Chuan joined us in May 2021 as chief financial officer. Prior to joining us, he was chief financial officer of Huazhu Group from November 2015 to May 2021, and was the chief financial officer for Rnomac International Limited, from November 2011 to August 2015. Mr. Teo worked in DDB Greater China Group, was appointed as the chief financial officer in September 2009, and was additionally appointed as the director of operations in January 2011. He previously served in Focus Media Group and was appointed as the financial deputy director in June 2007. Prior to that, from September 1994 to May 2007, Mr. Teo worked at Ernst & Young and Ernst & Young Business Services Ltd. in various positions in Kuala Lumpur and Toronto, including as a senior manager in the Transaction Advisory Services. Mr. Teo has been an independent director of 111, Inc. (a company listed on the NASDAQ, ticker symbol: YI) since September 2018. Mr. Teo received his Bachelor of Science in Accounting and Financial Analysis degree from The University of Warwick in the United Kingdom in July 1994. He is a Chartered Certified Accountant in the United Kingdom, who has obtained his qualification in July 1998 from The Association of Chartered Certified Accountants, and is a Certified Public Accountant in the United States and Hong Kong, who has obtained his qualification from American Institute of Certified Public Accountants in May 2002 and Hong Kong Society of Accountants in October 2003, respectively.
This will close in 0 seconds
Dr TJ Deng joined BioDuro in the initial stages of the company and helped BioDuro grow to an industry leading discovery services organization. He established and managed several scientific departments, including DMPK, before transitioning to a leader of the business and operations functions. Prior to joining BioDuro, Dr. Deng spent six years at PPD, in positions with increasing responsibilities from scientist to scientific manager.
Achievements
This will close in 0 seconds
Kent is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. He combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. He has successfully led the geographic expansion of businesses into Europe, Asia, South America in addition to the United States.
He also currently serves as a board member for Goodwin Biotechnologies (a biological contract manufacturer), and board advisor for Vitruvias Therapeutics (a specialty generic pharmaceutical business)
Achievements
This will close in 0 seconds
Achievements
This will close in 0 seconds
Roy has over 25 years of healthcare industry experience. He started his career as an orthopedic surgeon. Roy joined Eli Lilly as a sales rep in 1997. Since then he has had various roles in market research, business intelligence, BU head, strategy, regional general management, business development etc., both at Eli Lilly and Boehringer Ingelheim (BI). Roy also spent more than two years in Germany where he was BI’s Director of Corporate Business and Enabling Strategy.
Roy obtained a bachelor’s degree in Clinical Medicine at Zhejiang Traditional Chinese Medicine University, and an MBA from Zhejiang University.
Achievements
This will close in 0 seconds
San Diego/圣地亚哥
Our San Diego site is our corporate headquarters. The facility is home to BioDuro’s drug product development technologies and has 9 GMP clean rooms. Development and manufacturing operations are conducted for projects up to Phase III clinical trials.
Size: 44,000 sq. ft.
Featured capabilites: Tableting, Coating, Hot Melt Extrusion, Spray Dried Dispersion
11011 Torreyana Rd.
San Diego
CA 92121
United States
This will close in 0 seconds
Beijing/北京
Size: 100,000 sq. ft.
Featured capabilities: Radioactivity Lab, Monoclonal Antibody Discovery, Medicinal Chemistry
No. 29 Life Science Park Road
Changping District Beijing,
102206
P.R. China
This will close in 0 seconds
Shanghai-Waigaoqiao/上海-外高桥
Established in 2012, BioDuro’s Shanghai facility has been growing with its departments. The cutting edge facility contains labs for ADME, bioanalysis, in vitro assays and translational research. The site includes a 18,000 sq. ft vivarium and 20,000 sq. ft of office space.
Size: 92,000 sq. ft.
Featured capabilities: Scale-up Chemistry, Discovery Biology, DMPK, In Vivo Pharmacology
No. 233 North Fu Te Road
Waigaoqiao Free Trade Zone
Shanghai, 200131
P.R. China
This will close in 0 seconds
Cathy joined the Board of Directors of BioDuro-Sundia in 2020, with the Advent-led acquisition of Sundia and creation of BioDuro-Sundia. Prior to that, she was Chairman of the Board at Sundia Meditech Group, where she was the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia solidified its position as one of the leading pre-clinical CROs in China.
This will close in 0 seconds
Wuxi/无锡
Established in 2019, BioDuro-Sundia’s fully integrated discovery facility located at the heart of Jiangsu Wuxi Life Science & Technology Industrial Park with plans of growing staff to 1000+ scientists
Size: 300,000 sq. ft.
Featured capabilities:
Discovery Chemistry & Biologics, Biology, DMPK, Pharmacology, CMC Services
no.1699,Huishan avenue
Huishan Economic
Development Zone,Wuxi
P.R. China
This will close in 0 seconds
Hebei/河北
Size: 45,208 sq. ft.
Featured capabilities: SFFS Chemistry: mg to kg scale up
(150 hood)
238 Changjiang Road
Shijiazhuang,
Hebei province
P.R. China
This will close in 0 seconds
Taiwan/台湾
Size: 3,352sq.ft.
Featured capabilities: Chemistry；Biology
7F, No. 107, Sec. 4
Ren Ai Road,
Da-an District,
Taipei, Taiwan
This will close in 0 seconds
Bengbu/蚌埠
Size: 43,056 sq. ft.
Featured capabilities: Intermediates, GMP starting materials
Mohekou Industrial Park,
Huaishang District, Bengbu,
Anhui province
P.R. China
This will close in 0 seconds
Shanghai-Changli/上海-长利园区
Our Shanghai-Changli site supports FTE cheimistry and advanced Discovery Chemistry processes.z
Size: 71,844 sq. ft.
Featured capabilities: Chiral Analytical Lab, Analytical and Purification Lab, NMR Lab, Synthetic Lab, Parallel Synthesis Lab, Flash Chromatography Lab..(380 hoods)
法拉第路251号8号楼;
Building 8, 251 Faladi Road,
Zhangjiang Hi-Tech Park,
Shanghai,China
P.R. China
This will close in 0 seconds
Shanghai-Halei/上海哈雷园区
Size: 31,043 sq. ft.
Featured capabilities: Formulation : Preformulation, Wet Granulation, Compression, Tablet Coating, Fluid Bed Room, Spray Dryer, Hot Melt Extrusion, Dry Granulation Biology: Kinase selectivity, Cellular Assay, Compound Screen, Immune oncology service
哈雷路917弄1号;
Building 1, 917 Halei Road,
Zhangjiang Hi-Tech Park,
Shanghai,China
This will close in 0 seconds
Shanghai-Kelun/上海-克伦
Size: 98,503 sq. ft.
Featured capabilities: general chemistry; Process: GMP & non-GMP kilo lab, Process analytical, Column Purification , Flow Chemistry. Analytical: 22 HPLC/UPLC. 8 Stability Chambers . DMPK: animal PK, Bioanlysis Metabolite ID, In Vitro Studies, In- Life studies
Building 8, 388 Jialilue Road,
Zhangjiang Hi-Tech Park,
Shanghai China, 201203
This will close in 0 seconds